Hänni P - Search Results

1

Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.

Lorscheider J, Benkert P, Lienert C, Hänni P, Derfuss T, Kuhle J, Kappos L, Yaldizli Ö. Lorscheider J, et al. Among authors: hanni p. Mult Scler. 2018 May;24(6):777-785. doi: 10.1177/1352458518768433. Epub 2018 Apr 24. Mult Scler. 2018. PMID: 29685071

2

Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment.

von Wyl V, Décard BF, Benkert P, Lorscheider J, Hänni P, Lienert C, Kuhle J, Derfuss T, Kappos L, Yaldizli Ö. von Wyl V, et al. Among authors: hanni p. Eur J Neurol. 2020 Jun;27(6):1066-1075. doi: 10.1111/ene.14191. Epub 2020 Apr 3. Eur J Neurol. 2020. PMID: 32097512

3

Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.

von Wyl V, Benkert P, Moser A, Lorscheider J, Décard B, Hänni P, Lienert C, Kuhle J, Derfuss T, Kappos L, Yaldizli Ö. von Wyl V, et al. Among authors: hanni p. Mult Scler. 2021 Mar;27(3):439-448. doi: 10.1177/1352458520918489. Epub 2020 May 28. Mult Scler. 2021. PMID: 32463336

4

Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.

Lorscheider J, Benkert P, Lienert C, Hänni P, Derfuss T, Kuhle J, Kappos L, Yaldizli Ö. Lorscheider J, et al. Among authors: hanni p. J Neurol. 2021 Mar;268(3):941-949. doi: 10.1007/s00415-020-10226-6. Epub 2020 Sep 24. J Neurol. 2021. PMID: 32974794 Free PMC article.

5

Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis.

Müller J, Schädelin S, Lorscheider J, Benkert P, Hänni P, Schmid J, Kuhle J, Derfuss T, Granziera C, Yaldizli Ö. Müller J, et al. Among authors: hanni p. Eur J Neurol. 2023 Dec;30(12):3809-3818. doi: 10.1111/ene.16044. Epub 2023 Aug 29. Eur J Neurol. 2023. PMID: 37578431

6

Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis.

Müller J, Roos I, Kalincik T, Lorscheider J, Galli E, Benkert P, Schädelin S, Sharmin S, Einsiedler M, Hänni P, Schmid J, Kuhle J, Derfuss T, Granziera C, Ziemssen T, Siepmann T, Yaldizli Ö. Müller J, et al. Among authors: hanni p. Brain Behav. 2024 May;14(5):e3498. doi: 10.1002/brb3.3498. Brain Behav. 2024. PMID: 38688877 Free PMC article.

7

How the forebrain transitions to adulthood: developmental plasticity markers in a long-lived rodent reveal region diversity and the uniqueness of adolescence.

Garduño BM, Hanni P, Hays C, Cogram P, Insel N, Xu X. Garduño BM, et al. Among authors: hanni p. Front Neurosci. 2024 Feb 22;18:1365737. doi: 10.3389/fnins.2024.1365737. eCollection 2024. Front Neurosci. 2024. PMID: 38456144 Free PMC article.

8

Vocal cord dysfunction: an important differential diagnosis of brittle asthma.

Borer H, Hänni P, Schoenenberger RA. Borer H, et al. Among authors: hanni p. Respiration. 2001;68(3):318. doi: 10.1159/000050517. Respiration. 2001. PMID: 11416255 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters